Intuitive Surgical (ISRG) Is Becoming a Procedure-Growth Compounder

Investors often treat Intuitive Surgical (ISRG) like a capital-equipment company whose story rises and falls with quarterly robot placements. That lens is understandable, because system placements are visible, easy to compare, and usually dominate the headline numbers after each earnings release. But it is no longer the best way to understand the business. Intuitive increasingly looks like a procedure-growth ecosystem whose economics are driven by what happens after a system is installed: recurring instrument usage, service contracts, operating leases, and rising utilization across a large installed base.

That distinction matters because it changes the core investor question. Instead of asking whether a given quarter delivered enough robot sales, investors should ask whether Intuitive is deepening a durable clinical and financial ecosystem that can keep producing higher procedure volume and recurring revenue over time. The latest full-year and first-quarter data suggest the answer is increasingly yes, even if that thesis still depends on hospital spending, utilization discipline, and margin execution.

Why Intuitive is bigger than a robot-placement story

The cleanest evidence comes from Intuitive’s revenue mix. In fiscal 2025, the company generated about $10.06 billion in revenue, up 21% from 2024. But the more important number is that $8.47 billion of that total came from recurring revenue streams: instruments and accessories, service, and operating leases. That recurring base was up from $7.04 billion in 2024 and represented 84% of total revenue in both years.

That is not the profile of a company whose economics depend mainly on one-time hardware sales. Systems revenue did rise strongly in 2025, increasing 26% to $2.47 billion from $1.97 billion in 2024. But the larger engine remained the recurring ecosystem around each system once it was placed. Instruments and accessories revenue reached about $6.02 billion in 2025, service revenue rose 20% to $1.57 billion, and operating lease revenue climbed to $874.3 million from $654.2 million a year earlier.

The reason this model is durable is simple. A da Vinci placement is not the end of a sale cycle. It is the start of a long stream of procedure-linked spending. Each procedure drives fresh demand for proprietary instruments and accessories. Each installed system needs service and support. And when hospitals use leases instead of upfront purchases, Intuitive turns adoption into a recurring payment stream rather than a single hardware event.

That is why focusing only on quarterly placements can mislead investors. Placements still matter because they expand the platform, but the real quality of the business is determined by how much activity that installed base generates over time.

What the latest numbers say about recurring revenue and installed-base quality

The installed-base data show why this model continues to strengthen. As of December 31, 2025, Intuitive’s da Vinci installed base stood at about 11,106 systems, up from about 9,902 a year earlier. The Ion installed base reached about 995 systems, up from about 805 in 2024. By March 31, 2026, the da Vinci installed base had grown further to 11,395 systems, while Ion reached 1,041 systems.

Just as important, procedure growth is keeping pace in a way that supports revenue quality rather than just footprint expansion. In 2025, about 3,153,000 surgical procedures were performed using da Vinci systems, up about 18% from roughly 2,683,000 in 2024. Full-year worldwide procedures across da Vinci and Ion grew about 19%. In the first quarter of 2026, worldwide procedures grew about 17%, with da Vinci procedures up about 16% and Ion procedures up about 39%.

Those usage trends matter because the highest-quality revenue lines are tied directly to utilization. In Q1 2026, instruments and accessories revenue increased 23% to $1.69 billion from $1.37 billion a year earlier, faster than system revenue growth on a dollar basis and closely aligned with procedure growth. Systems revenue also rose meaningfully, to $651 million from $523 million, but the bigger signal is that consumables continue to scale with clinical usage.

Management also reported that full-year 2025 da Vinci system utilization increased 3% relative to 2024, and fourth-quarter 2025 average utilization rose 4% year over year. That is an important detail. A larger installed base alone can produce growth, but improving utilization shows that existing systems are doing more work, which usually supports stronger recurring revenue economics.

Why da Vinci 5 and procedure growth matter more together than separately

The da Vinci 5 rollout is easy to interpret as a hardware refresh cycle, but that would undersell its importance. In 2025, Intuitive placed 1,721 da Vinci systems, including 870 da Vinci 5 systems. In Q1 2026 alone, it placed 431 da Vinci systems, and 232 of those were da Vinci 5 units.

That matters, but not just because a new platform can lift system sales. The stronger thesis is that da Vinci 5 can expand the downstream economics of the installed base. Newer systems help keep hospitals inside Intuitive’s ecosystem, support broader procedural adoption, and can improve the mix of instruments, accessories, and service opportunities attached to each placement. In other words, the platform transition matters most when it reinforces the recurring model rather than when it is viewed as a standalone equipment cycle.

The lease model strengthens that interpretation. Operating lease revenue reached $874.3 million in 2025, up from $654.2 million in 2024, showing that Intuitive is willing to reduce adoption friction for hospitals while deepening long-duration revenue streams. Leasing can make near-term system revenue look smaller than an outright sale would have, but it can improve the durability of future revenue and widen access to the platform.

The interaction between placements and procedures is the real point. More systems create more potential procedure capacity. More procedures create more recurring revenue and strengthen the clinical habit of using the platform. That feedback loop is what makes Intuitive look increasingly like a compounder rather than a conventional medtech hardware vendor.

What investors should watch next: utilization, margin pressure, and hospital spending

The bullish interpretation is not risk-free. First, growth is still partly constrained by hospital budgets and capital planning cycles. Even with leasing options, hospitals do not make robotic-surgery decisions in a vacuum. If capital spending tightens, placements can slow, which would affect the pace of future installed-base expansion.

Second, procedure growth is moderating from a very strong 2025 base. Management guided for full-year 2026 worldwide da Vinci procedure growth of about 13.5% to 15.5%, below the roughly 18% da Vinci procedure growth delivered in 2025. That is still healthy, but it means investors should watch whether utilization stays strong enough to preserve the recurring-revenue thesis as comparisons get harder.

Third, margins deserve attention. Gross profit as a percentage of revenue declined to 66.0% in 2025 from 67.5% in 2024. For 2026, management guided to non-GAAP gross profit margin of 67.5% to 68.5% of revenue, but that guidance includes an estimated tariff impact equal to about 1.0% of revenue. That makes tariffs an explicit new headwind, even for a business with strong procedural momentum.

Still, Intuitive’s financial flexibility remains substantial. The company ended 2025 with $9.03 billion in cash, cash equivalents, and investments, and it ended Q1 2026 with $7.98 billion. It also repurchased 2.3 million shares for $1.1 billion in the first quarter of 2026. That balance-sheet strength gives management room to keep investing through a platform transition without turning the story into a financing problem.

The most useful way to frame ISRG now is this: system placements still matter, but they matter most as inputs into a larger recurring ecosystem. If installed-base growth, procedure growth, and utilization continue to reinforce one another, Intuitive should keep looking less like a robot seller and more like a durable procedure-driven platform.

Key Signals for Investors

• If procedure growth remains in the mid-teens even as system placements normalize, the recurring-revenue thesis should stay intact.
• Rising da Vinci 5 adoption matters most if it lifts downstream instruments, accessories, and service economics rather than just near-term hardware revenue.
• Gross-margin performance in 2026 will show whether tariffs and platform-transition costs are temporary friction or a more persistent drag.
• Hospital budget discipline remains the main external variable, because weaker capital spending could slow installed-base expansion before recurring revenue fully offsets it.